Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo.

Cited by (1,003)

Items 201–300 of 1,003

1. Tumour-targeted delivery of TRAIL using Salmonella typhimurium enhances breast cancer survival in mice
   Sabha Ganai, Richard B. Arenas, Neil S. Forbes · 2009 · British Journal of Cancer
2. HDAC inhibitors enhance the apoptosis-inducing potential of TRAIL in breast carcinoma
   Thiyam Ramsing Singh, Sharmila Shankar, Rakesh K. Srivastava · 2005 · Oncogene
3. TRAIL induces apoptosis in triple-negative breast cancer cells with a mesenchymal phenotype
   Monzur Rahman, Sean R. Davis, Janet G. Pumphrey, Jing Bao, Marion M. Nau, Paul S. Meltzer, Stanley Lipkowitz · 2008 · Breast Cancer Research and Treatment
4. Non-canonical kinase signaling by the death ligand TRAIL in cancer cells: discord in the death receptor family
   Kaamar Azijli, B Weyhenmeyer, Godefridus J. Peters, Steven de Jong, Frank A.E. Kruyt · 2013 · Cell Death and Differentiation
5. TNF-related apoptosis-inducing ligand (TRAIL): A new path to anti-cancer therapies
   Peter A. Holoch, Thomas S. Griffith · 2009 · European Journal of Pharmacology
6. Effects of tumor necrosis factor-related apoptosis-inducing ligand alone and in combination with chemotherapeutic agents on patients' colon tumors grown in SCID mice.
   Takuji Naka, Kenji Sugamura, Bonnie Lee Hylander, Michael B. Widmer, Youcef M. Rustum, Elizabeth A. Repasky · 2002 · PubMed
7. Purification and characterization of recombinant spider silk expressed in Escherichia coli
   Steven M. Arcidiacono, C. Mello, David Lee Kaplan, Stephen Cheley, Hagan Bayley · 1998 · Applied Microbiology and Biotechnology
8. Proteasome Inhibitor MG132 Induces Death Receptor 5 through CCAAT/Enhancer-Binding Protein Homologous Protein
   Tatsushi Yoshida, Takumi Shiraishi, Susumu Nakata, Mano Horinaka, Miki Wakada, Yoichi Mizutani, Tsuneharu Miki, Toshiyuki Sakai · 2005 · Cancer Research
9. Critical roles of TRAIL in hepatic cell death and hepatic inflammation
   Shijun J. Zheng, Pu Wang, Galit Tsabary, Youhai H. Chen · 2004 · Journal of Clinical Investigation
10. Expression of TRAIL and TRAIL receptors in normal and malignant tissues
    Raymond A DANIELS, Helen Turley, Fiona C. Kimberley, Xue Song LIU, Juthathip Mongkolsapaya, Paul CH'EN, Xiao Ning Xu, Boquan Jin, Francesco Pezzella, Gavin Robert Screaton · 2005 · Cell Research
11. TRAIL and cancer therapy
    Frank A.E. Kruyt · 2008 · Cancer Letters
12. Chemoresistance in solid tumours
    Timothy Richard Wilson, Daniel B. Longley, Patrick G. Johnston · 2006 · Annals of Oncology
13. TRAIL as a target in anti-cancer therapy
    Gen Sheng Wu · 2009 · Cancer Letters
14. TRAIL in cancer therapy: present and future challenges
    Delphine Mérino, Najoua Lalaoui, Alexandre Morizot, Éric Solary, Olivier Micheau · 2007 · Expert Opinion on Therapeutic Targets
15. White paper on microbial anti-cancer therapy and prevention
    Neil S. Forbes, Robert S. Coffin, Liang Deng, Laura Evgin, Steven Fiering, Matthew J. Giacalone, Claudia Gravekamp, James L. Gulley, Hal Gunn, Robert M. Hoffman et al. · 2018 · Journal for ImmunoTherapy of Cancer
16. Proteasome Inhibition Sensitizes Hepatocellular Carcinoma Cells, But Not Human Hepatocytes, to TRAIL *
    Tom M. Ganten, Ronald Koschny, Tobias L. Haas, Jaromir Sykora, Min Li‐Weber, Kerstin Herzer, Henning Walczak · 2005 · Hepatology
17. TRAIL Induces Apoptosis and Inflammatory Gene Expression in Human Endothelial Cells
    Jie Hui Li, Nancy C. Kirkiles-Smith, Jennifer Madison McNiff, Jordan S. Pober · 2003 · The Journal of Immunology
18. Phase 2 study of mapatumumab, a fully human agonistic monoclonal antibody which targets and activates the TRAIL receptor-1, in patients with advanced non-small cell lung cancer
    F. Anthony Greco, Philip Bonomi, Jeffrey Crawford, Karen L. Kelly, Yun W. Oh, Wendy Halpern, Larry Lo, Gilles Gallant, Jerry L. Klein · 2008 · Lung Cancer
19. c-Jun NH2-Terminal Kinase-Mediated Up-regulation of Death Receptor 5 Contributes to Induction of Apoptosis by the Novel Synthetic Triterpenoid Methyl-2-Cyano-3,12-Dioxooleana-1, 9-Dien-28-Oate in Human Lung Cancer Cells
    Wei Zou, Xiangguo Liu, Ping Yue, Zhongmei Zhou, Michael B. Sporn, Reuben Lotan, Fadlo Raja Khuri, Shi‐Yong Sun · 2004 · Cancer Research
20. Acceleration of Human Neutrophil Apoptosis by TRAIL
    Stephen A. Renshaw, Jasvir Singh Parmar, Vanessa Singleton, Sarah J. Rowe, David Harold Dockrell, Steven Dower, Colin D. Bingle, Edwin R. Chilvers, Moira K. B. Whyte · 2003 · The Journal of Immunology
21. Mutations in apoptosis genes: a pathogenetic factor for human disease
    Leonhard Müllauer, Petra Gruber, David Sebinger, Judith Buch, Sabine Wohlfart, Andreas Chott · 2001 · Mutation Research/Reviews in Mutation Research
22. TNF-related apoptosis-inducing ligand (TRAIL) as a negative regulator of normal human erythropoiesis.
    Loris Zamai, Paola Secchiero, Sabina Pierpaoli, Alessandra Bassini, Stefano Papa, Emad S. Alnemri, Lia Guidotti, Marco Vitale, Giorgio Zauli · 2000 · PubMed
23. MiR-494 is regulated by ERK1/2 and modulates TRAIL-induced apoptosis in non–small-cell lung cancer through BIM down-regulation
    Giulia Romano, Mario Acunzo, Michela Garofalo, Gianpiero Di Leva, Luciano Cascione, Ciro Zanca, Brad N. Bolon, Gerolama Condorelli, Carlo Maria Croce · 2012 · Proceedings of the National Academy of Sciences
24. TRAIL activates acid sphingomyelinase via a redox mechanism and releases ceramide to trigger apoptosis
    Claudia Alexandra Dumitru, Erich Gulbins · 2006 · Oncogene
25. Activation of ERK1/2 protects melanoma cells from TRAIL-induced apoptosis by inhibiting Smac/DIABLO release from mitochondria
    Xu Dong Zhang, Jodie M. Borrow, Xi Yi Zhang, Tam Thuan Nguyen, Peter Hersey · 2003 · Oncogene
26. Playing the DISC: Turning on TRAIL death receptor-mediated apoptosis in cancer
    Bodvaël Pennarun, Annemieke Meijer, Elisabeth G.E. de Vries, Jan H. Kleibeuker, Frank A.E. Kruyt, Steven de Jong · 2009 · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer
27. T cells require TRAIL for optimal graft-versus-tumor activity
    Cornelius Schmaltz, Önder Alpdoğan, Barry J. Kappel, Stephanie J. Muriglan, Jimmy A. Rotolo, Jennifer Ongchin, Lucy M. Willis, Andrew S. Greenberg, Jeffrey M. Eng, James M. Crawford et al. · 2002 · Nature Medicine
28. The functional significance of microRNA-145 in prostate cancer
    Mohd Saif Zaman, Y Chen, G Deng, Varahram Shahryari, Seong O Suh, Sharanjot Saini, S Majid, J Liu, Gaurav Khatri, Yuichiro Tanaka et al. · 2010 · British Journal of Cancer
29. Dynamics within the CD95 death‐inducing signaling complex decide life and death of cells
    Leo Neumann, Carina Pforr, Joël Beaudouin, Alexander Pappa, Nicolai Fricker, Peter H. Krammer, Inna N. Lavrik, Roland Eils · 2010 · Molecular Systems Biology
30. Ectopic overexpression of second mitochondria-derived activator of caspases (Smac/DIABLO) or cotreatment with N-terminus of Smac/DIABLO peptide potentiates epothilone B derivative–(BMS 247550) and Apo-2L/TRAIL–induced apoptosis
    Fei Guo, Ramadevi Nimmanapalli, Shanthi R. Paranawithana, Sylvie Wittmann, David Ray Griffin, Purva Bali, Erica O’Bryan, Carlos Fumero, Hong‐Gang Wang, Kapil N. Bhalla · 2002 · Blood
31. IFNα-stimulated neutrophils and monocytes release a soluble form of TNF-related apoptosis-inducing ligand (TRAIL/Apo-2 ligand) displaying apoptotic activity on leukemic cells
    Cristina Tecchio, Veronica Huber, Patrizia Scapini, Federica Calzetti, Daniela Margotto, Giuseppe Todeschini, Lorenzo Pilla, Giovanni Martinelli, Giovanni Pizzolo, Licia Rivoltini et al. · 2004 · Blood
32. TRAIL Agonists on Clinical Trials for Cancer Therapy: The Promises and the Challenges
    Anita C. Bellail, Ling Qi, Patrick Mulligan, Vaninder S. Chhabra, Chunhai Hao · 2009 · Reviews on Recent Clinical Trials
33. TRAIL receptor-targeted therapeutics: Resistance mechanisms and strategies to avoid them
    Andrew M. Thorburn, Kian Behbakht, Heide L. Ford · 2008 · Drug Resistance Updates
34. Alterations of the DR5/TRAIL receptor 2 gene in non-small cell lung cancers.
    S H Lee, Min Sun Shin, Hong Sug Kim, H K Lee, Won Sang Park, Su Young Kim, J H Lee, S Y Han, Jik Young Park, Ro Ra Oh et al. · 1999 · PubMed
35. Synergistic induction of tumor cell apoptosis by death receptor antibody and chemotherapy agent through JNK/p38 and mitochondrial death pathway
    Toshiaki Ohtsuka, Donald J. Buchsbaum, Patsy G. Oliver, Sharmila K. Makhija, Robert P. Kimberly, Tong Zhou · 2003 · Oncogene
36. Curcumin (diferuloyl-methane) enhances tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in LNCaP prostate cancer cells.
    Dorrah Deeb, Yong X. Xu, Hao Jiang, Xiaohua Gao, Nalini Janakiraman, Robert Chapman, Subhash C. Gautam · 2003 · PubMed
37. 2.8 Å Resolution Crystal Structure of Human TRAIL, a Cytokine with Selective Antitumor Activity
    Sun‐Shin Cha, Min‐Sung Kim, Yo Han Choi, Byungje Sung, Nam Kyu Shin, Hang‐Cheol Shin, Young Chul Sung, Byung‐Ha Oh · 1999 · Immunity
38. Inhalable self-assembled albumin nanoparticles for treating drug-resistant lung cancer
    Seong Ho Choi, Hyeong Jun Byeon, Ji Su Choi, Lequang Thao, In‐Soo Kim, Eun Seong Lee, Beom Soo Shin, Kang Choon Lee, Yu Seok Youn · 2014 · Journal of Controlled Release
39. Apo2L/TRAIL and the Death Receptor 5 Agonist Antibody AMG 655 Cooperate to Promote Receptor Clustering and Antitumor Activity
    Jonathan D. Graves, Jennifer J. Kordich, Tzu-Hsuan Huang, Julia Piasecki, Tammy L. Bush, Timothy Sullivan, Ian N. Foltz, Wesley Chang, Heather Douangpanya, Thu Dang et al. · 2014 · Cancer Cell
40. Active Caspases and Cleaved Cytokeratins Are Sequestered into Cytoplasmic Inclusions in Trail-Induced Apoptosis
    Marion MacFarlane, Wendy Merrison, Dr David Dinsdale, Gerald M. Cohen · 2000 · The Journal of Cell Biology
41. Characterization of 8p21.3 chromosomal deletions in B-cell lymphoma: TRAIL-R1 and TRAIL-R2 as candidate dosage-dependent tumor suppressor genes
    Rubio-Moscardo, F. · 2005 · Blood
42. Chemotherapy and TRAIL-mediated colon cancer cell death: the roles of p53, TRAIL receptors, and c-FLIP
    Leeona Galligan, Daniel B. Longley, Miranda V. McEwan, Timothy Richard Wilson, Kirsty M. McLaughlin, Patrick G. Johnston · 2005 · Molecular Cancer Therapeutics
43. TRAIL receptor signaling and therapeutics
    Junaid Abdulghani, Wafik S. El‐Deiry · 2010 · Expert Opinion on Therapeutic Targets
44. Identification of Inhibitors of TRAIL-induced Death (ITIDs) in the TRAIL-sensitive Colon Carcinoma Cell Line SW480 Using a Genetic Approach
    Timothy Francis Burns, Wafik S. El‐Deiry · 2001 · Journal of Biological Chemistry
45. Trail induces cell migration and invasion in apoptosis-resistant cholangiocarcinoma cells
    Norihisa Ishimura, Hajime Isomoto, Steven F. Bronk, Gregory James Gores · 2005 · American Journal of Physiology-Gastrointestinal and Liver Physiology
46. Model-based dissection of CD95 signaling dynamics reveals both a pro- and antiapoptotic role of c-FLIPL
    Fricker, Nicolai, Beaudouin, Joel, Richter, Petra, Eils, Roland, Krammer, Peter H., Lavrik, Inna N. · 2010 · Journal of Cell Biology
47. Inhibition of human lung cancer growth following adenovirus-mediated mda-7 gene expression in vivo
    知行 佐伯, Abner M. Mhashilkar, Xin Swanson, X. Helena Zou-Yang, Kerry Sieger, Shinichiro Kawabe, Cynthia D. Branch, Louis A. Zumstein, Raymond E. Meyn, Jack A. Roth et al. · 2002 · Oncogene
48. Requirement of p53 targets in chemosensitization of colonic carcinoma to death ligand therapy
    Shulin Wang, Wafik S. El‐Deiry · 2003 · Proceedings of the National Academy of Sciences
49. mTOR Controls FLIPS Translation and TRAIL Sensitivity in Glioblastoma Multiforme Cells
    Amith Panner, Charles David James, Mitchel Stuart Berger, Russell O. Pieper · 2005 · Molecular and Cellular Biology
50. In situ growth of a PEG-like polymer from the C terminus of an intein fusion protein improves pharmacokinetics and tumor accumulation
    Weiping Gao, Wenge Liu, Trine Christensen, Michael R. Zalutsky, Ashutosh Chilkoti · 2010 · Proceedings of the National Academy of Sciences
51. The Tumor Necrosis Factor-related Apoptosis-inducing Ligand Receptors TRAIL-R1 and TRAIL-R2 Have Distinct Cross-linking Requirements for Initiation of Apoptosis and Are Non-redundant in JNK Activation
    Frank Mühlenbeck, Pascal Schneider, Jean-Luc Bodmer, Ralph Schwenzer, Angelika Hauser, Gisela Schubert, Peter Scheurich, Dieter Moosmayer, Jürg Tschopp, Harald Wajant · 2000 · Journal of Biological Chemistry
52. Persistent c-FLIP(L) Expression Is Necessary and Sufficient to Maintain Resistance to Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand–Mediated Apoptosis in Prostate Cancer
    Xiaoping Zhang, Taiguang Jimmy Jin, Hongmei Yang, William C. DeWolf, Roya Khosravi‐Far, Aria F. Olumi · 2004 · Cancer Research
53. Histone deacetylase inhibitors potentiate TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in lymphoid malignancies
    Satoshi Inoue, Marion MacFarlane, Nicholas W. Harper, Luise M.C. Wheat, Martin J.S. Dyer, Gerald M. Cohen · 2004 · Cell Death and Differentiation
54. Synergistic Induction of Apoptosis by the Combination of TRAIL and Chemotherapy in Chemoresistant Ovarian Cancer Cells
    Mauricio A. Cuello, Seth A. Ettenberg, Marion M. Nau, Stan Lipkowitz · 2001 · Gynecologic Oncology
55. Chronic lymphocytic leukemic cells exhibit apoptotic signaling via TRAIL-R1
    Marion MacFarlane, Satoshi Inoue, Susan L. Kohlhaas, Aneela Majid, Nicholas W. Harper, Daniel B. Kennedy, Martin J.S. Dyer, Gerald M. Cohen · 2005 · Cell Death and Differentiation
56. Tunicamycin Enhances Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand–Induced Apoptosis in Human Prostate Cancer Cells
    Takumi Shiraishi, Tatsushi Yoshida, Susumu Nakata, Mano Horinaka, Miki Wakada, Yoichi Mizutani, Tsuneharu Miki, Toshiyuki Sakai · 2005 · Cancer Research
57. An oncolytic adenoviral vector of Smac increases antitumor activity of TRAIL against HCC in human cells and in mice
    Zifei Pei, Liang Chu, Weiguo Zou, Zilai Zhang, Songbo Qiu, Rong Qi, Jinfa Gu, Cheng Qian, Xinyuan Liu · 2004 · Hepatology
58. Programmed Cell Death Pathways and Current Antitumor Targets
    Ming Tan, Jer Ping Ooi, Nawfal I Ismail, Ahmed Ismail Hassan Moad, Tengku Sifzizul Tengku Muhammad · 2009 · Pharmaceutical Research
59. Systemic Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand Delivery Shows Antiatherosclerotic Activity in Apolipoprotein E–Null Diabetic Mice
    Paola Secchiero, Riccardo Candido, Federica Corallini, Serena Zacchigna, Barbara Toffoli, Erika Rimondi, Bruno Fabris, Mauro Giacca, Giorgio Zauli · 2006 · Circulation
60. Involvement of Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand in NK Cell-Mediated and IFN-γ-Dependent Suppression of Subcutaneous Tumor Growth
    Kazuyoshi Takeda, Mark John Smyth, Erika Cretney, Yoshihiro Hayakawa, Noriko Yamaguchi, Hideo Yagita∥, Ko Okumura · 2001 · Cellular Immunology
61. Resistance mechanisms to cancer chemotherapy
    Kelly M. Redmond · 2008 · Frontiers in bioscience
62. Kaempferol sensitizes colon cancer cells to TRAIL-induced apoptosis
    Tatsushi Yoshida, Masako Konishi, Mano Horinaka, Takashi Yasuda, Ahmed E. Goda, Hiroya Taniguchi, Kimihiro Yano, Miki Wakada, Toshiyuki Sakai · 2008 · Biochemical and Biophysical Research Communications
63. Antitumor agent parthenolide reverses resistance of breast cancer cells to tumor necrosis factor-related apoptosis-inducing ligand through sustained activation of c-Jun N-terminal kinase
    Harikrishna Nakshatri, Susan E. Rice, Poornima Bhat‐Nakshatri · 2004 · Oncogene
64. Intracellular regulation of tumor necrosis factor–related apoptosis-inducing ligand–induced apoptosis in human multiple myeloma cells
    Nicholas Mitsiades, Constantine S. Mitsiades, Vassiliki Poulaki, Kenneth Carl Anderson, Steven Peter Treon · 2002 · Blood
65. Cysteine 230 Is Essential for the Structure and Activity of the Cytotoxic Ligand TRAIL
    Jean-Luc Bodmer, Pierre F. Meier, Jürg Tschopp, Pascal Schneider · 2000 · Journal of Biological Chemistry
66. Paclitaxel-induced apoptosis and mitotic arrest assessed by serial fine-needle aspiration: implications for early prediction of breast cancer response to neoadjuvant treatment.
    W. Fraser Symmans, Matthew D. Volm, Richard L. Shapiro, Alan Perkins, Alice Y. Kim, Sandra Demaria, Herman T. Yee, H McMullen, Ruth Oratz, Paula Klein et al. · 2000 · PubMed
67. Death receptor 5 mediated-apoptosis contributes to cholestatic liver disease
    Takeda, Kazuyoshi, Kojima, Yuko, Ikejima, Kenichi, Harada, Kenichi, Yamashina, Shunhei, Okumura, Kyoko, Aoyama, Tomonori, Frese, Steffen, Ikeda, Hiroko, Haynes, Nicole M. et al. · 2008 · Proceedings of the National Academy of Sciences
68. Structural and functional analysis of the interaction between the agonistic monoclonal antibody Apomab and the proapoptotic receptor DR5
    Adams, C, Totpal, K, Lawrence, D, Marsters, S, Pitti, R, Yee, S, Ross, S, Deforge, L, Koeppen, H, Sagolla, M et al. · 2008 · Cell Death & Differentiation
69. Apoptosis in hepatitis C virus infection
    Heike Bantel, Klaus Schulze‐Osthoff · 2003 · Cell Death and Differentiation
70. Albumin-based nanoparticles: a promising strategy to overcome cancer drug resistance
    Islam A. Hassanin, Ahmed O. Elzoghby · 2020 · Cancer Drug Resistance
71. Constitutive activation of nuclear factor-κB prevents TRAIL-induced apoptosis in renal cancer cells
    Mototsugu Oya, Masafumi Ohtsubo, Atsushi Takayanagi, Masaaki Tachibana, Nobuyoshi Shimizu, Masaru Murai · 2001 · Oncogene
72. TRAIL Inhibits Tumor Growth but Is Nontoxic to Human Hepatocytes in Chimeric Mice
    Chunhai Hao, Jin Hyang Song, Belinda Hsi, Jamie T. Lewis, Doyoun K. Song, Kenneth C. Petruk, David Tyrrell, Norman M. Kneteman · 2004 · Cancer Research
73. NF-κB in cancer—a friend turned foe
    Rajani K. Ravi · 2004 · Drug Resistance Updates
74. Harnessing TRAIL-induced cell death for cancer therapy: a long walk with thrilling discoveries
    Antonella Montinaro, Henning Walczak · 2022 · Cell Death and Differentiation
75. Exosome-based delivery strategies for tumor therapy: an update on modification, loading, and clinical application
    Qian Yang, Shisheng Li, Haibo Ou, Yuming Zhang, Gangcai Zhu, Shaohong Li, Lanjie Lei · 2024 · Journal of Nanobiotechnology
76. Bortezomib and Depsipeptide Sensitize Tumors to Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand: A Novel Method to Potentiate Natural Killer Cell Tumor Cytotoxicity
    Andreas Lundqvist, Scott I. Abrams, David S. Schrump, Gauri Alvarez, Dante A. Suffredini, Maria Berg, Richard W. Childs · 2006 · Cancer Research
77. Apoptosis: implications of basic research for clinical oncology
    Ingo Tamm, Folke Schriever, Bernd Dörken · 2001 · The Lancet Oncology
78. Shared pathways: Death receptors and cytotoxic drugs in cancer therapy
    István Peták, Janet A. Houghton · 2001 · Pathology & Oncology Research
79. Cytokines and BCR-ABL mediate suppression of TRAIL-induced apoptosis through inhibition of forkhead FOXO3a transcription factor
    Saghi Ghaffari, Zainab Jagani, Claire Kitidis, Harvey F. Lodish, Roya Khosravi‐Far · 2003 · Proceedings of the National Academy of Sciences
80. Apoptosis in cancer—implications for therapy
    Henning Schulze‐Bergkamen, Peter H. Krammer · 2004 · Seminars in Oncology
81. The potential of TRAIL for cancer chemotherapy
    Motoo Nagane, H.-J. S. Huang, Webster K. Cavenee · 2001 · APOPTOSIS
82. Cardiac Glycosides Initiate Apo2L/TRAIL-Induced Apoptosis in Non–Small Cell Lung Cancer Cells by Up-regulation of Death Receptors 4 and 5
    Steffen Frese, Manuela Frese‐Schaper, Anne‐Catherine Andres, Daniela Miescher, Béatrice Zumkehr, Ralph Alexander Schmid · 2006 · Cancer Research
83. TNF-related apoptosis inducing ligand (TRAIL) and its receptors in tumor surveillance and cancer therapy
    Harald Wajant, Klaus Pfizenmaier, Peter Scheurich · 2002 · APOPTOSIS
84. Involvement of TRAIL and its receptors in viral hepatitis
    Bettina Mundt, Florian Kühnel, Lars Zender, Yasmin Paul, Hans Ludger Tillmann, Christian Trautwein, Michael Peter Manns, Stefan Kubicka · 2002 · The FASEB Journal
85. Gene therapy in the CNS
    Lauren C. Costantini, Joanna C. Bakowska, Xandra O. Breakefield, Ole Isacson A · 2000 · Gene Therapy
86. Increased hepatotoxicity of tumor necrosis factor–related apoptosis-inducing ligand in diseased human liver
    Xandra Volkmann, Ute Fischer, Matthias J. Bahr, Michael Ott, Frank Lehner, Marion MacFarlane, Gerald M. Cohen, Michael Peter Manns, Klaus Schulze‐Osthoff, Heike Bantel · 2007 · Hepatology
87. Expression of TRAIL (TNF‐related apoptosis‐inducing ligand) and its receptors in normal colonic mucosa, adenomas, and carcinomas
    Jan J. Koornstra, Jan H. Kleibeuker, Caroline M. M. van Geelen, Fleur E.M. Rijcken, Harry Hollema, Elisabeth G.E. de Vries, Steven de Jong · 2003 · The Journal of Pathology
88. Diosgenin induces death receptor-5 through activation of p38 pathway and promotes TRAIL-induced apoptosis in colon cancer cells
    C. Lepage, David Yannick Leger, Julian Bertrand, F. Martin, Jean‐Louis Beneytout, Bertrand Liagre · 2010 · Cancer Letters
89. Curcumin sensitizes prostate cancer cells to tumor necrosis factor-related apoptosis-inducing ligand/Apo2L by inhibiting nuclear factor-kappaB through suppression of IkappaBalpha phosphorylation.
    Dorrah Deeb, Hao Jiang, Xiaohua Gao, Mikehl S. Hafner, Henry K. Wong, George Divine, Robert Chapman, Scott A. Dulchavsky, Subhash C. Gautam · 2004 · PubMed
90. 2-methoxyestradiol up-regulates death receptor 5 and induces apoptosis through activation of the extrinsic pathway.
    Theresa M. LaVallee, Xiaoguo H. Zhan, Michelle Smith Johnson, Chris J Herbstritt, Glenn M. Swartz, Mark S Williams, Wendy A Hembrough, Shawn J. Green, Victor S. Pribluda · 2003 · PubMed
91. Tumor suppressor IRF‐1 mediates retinoid and interferon anticancer signaling to death ligand TRAIL
    Nicole M Clarke, Ana Maria Jimenez-Lara, Emilie Voltz, Hinrich Gronemeyer · 2004 · The EMBO Journal
92. Extracellular Vesicles in Cancer Drug Resistance: Roles, Mechanisms, and Implications
    Qiurong Yang, Jing Bo Xu, Jianmei Gu, Hui Shi, Jiayin Zhang, Jianye Zhang, Zhe‐Sheng Chen, Xinjian Fang, Taofeng Zhu, Xu Zhang · 2022 · Advanced Science
93. A Novel AP-1 Element in the CD95 Ligand Promoter Is Required for Induction of Apoptosis in Hepatocellular Carcinoma Cells upon Treatment with Anticancer Drugs
    Sören T. Eichhorst, Martina Müller, Min Li‐Weber, Henning Schulze‐Bergkamen, Peter E. Angel, Peter H. Krammer · 2000 · Molecular and Cellular Biology
94. Antitumor efficacy of TRA-8 anti-DR5 monoclonal antibody alone or in combination with chemotherapy and/or radiation therapy in a human breast cancer model.
    Donald J. Buchsbaum, Tong Zhou, William E. Grizzle, Patsy G. Oliver, Charlotte Hammond, Sijian Zhang, Mark Carpenter, Albert F. LoBuglio · 2003 · PubMed
95. Doxorubicin-loaded porous PLGA microparticles with surface attached TRAIL for the inhalation treatment of metastatic lung cancer
    In‐Soo Kim, Hyeong Jun Byeon, Tae Hyung Kim, Eun Seong Lee, Kyung Taek Oh, Beom Soo Shin, Kang Choon Lee, Yu Seok Youn · 2013 · Biomaterials
96. Expression of TRAIL and TRAIL death receptors in stage III non-small cell lung cancer tumors.
    Diana C.J. Spierings, Elisabeth G.E. de Vries, Wim Timens, Harry J.M. Groen, H. Marike Boezen, Steven de Jong · 2003 · PubMed
97. Co-delivery of pEGFP-hTRAIL and paclitaxel to brain glioma mediated by an angiopep-conjugated liposome
    Xiyang Sun, Zhiqing Pang, Hongxing Ye, Bo Qiu, Liangran Guo, Jingwei Li, Jinfeng Ren, Yong jun Qian, Qizhi Zhang, Jun Chen et al. · 2011 · Biomaterials
98. Exploiting the hallmarks of cancer
    George W. Sledge, Kathy D. Miller · 2003 · European Journal of Cancer
99. Prospects for targeting the Bcl-2 family of proteins to develop novel cytotoxic drugs
    Jonathan B. Baell, David C.S. Huang · 2002 · Biochemical Pharmacology
100. Caspase‐2 primes cancer cells for TRAIL‐mediated apoptosis by processing procaspase‐8
     Soonah Shin, Yoonmi Lee, Wooseok Kim, Hyeonseok Ko, Hye-Yeon Choi, Kunhong Kim · 2005 · The EMBO Journal